文献速递肝病

晚期肝硬化中的口腔-肠道微生物组相互作用:致病性肠型与唾液型、毒力因子及抗菌药物耐药性的特征分析

Oral-gut microbiome interactions in advanced cirrhosis: characterisation of pathogenic enterotypes and salivatypes, virulence factors and antimicrobial resistance.
PubMed 文献 · J Hepatol · 2024-10-22

本研究对15例健康对照、26例稳定期肝硬化、46例失代偿期肝硬化、14例慢加急性肝衰竭及14例无肝硬化严重感染患者进行配对唾液和粪便宏基因组测序,分析口腔-肠道微生物组结构、毒力因子和耐药基因。结果显示口腔-肠道微生物重叠、毒力因子频率和耐药基因均随肝硬化严重程度显著增加,致病菌逐渐占优势而共生菌减少。

要点

  • 随着肝硬化严重程度和高氨血症增加,唾液型和肠型中致病菌比例增加、常驻菌减少。
  • 失代偿期肝硬化和慢加急性肝衰竭患者口腔与肠道微生物组重叠增加,独立于抗菌药、β受体阻滞剂和抑酸治疗。
  • 失代偿期肝硬化和慢加急性肝衰竭患者中检出大量抗菌药物耐药基因(口腔1218个、肠道672个),且肝硬化耐药组独特。

核心结论

  • 口腔-肠道微生物群落重叠程度、毒力因子频率和抗菌药物耐药基因均随肝硬化严重程度显著增加,致病菌逐渐占优势而共生菌减少。
  • 尽管抗菌药物暴露相似,失代偿期肝硬化和慢加急性肝衰竭患者较无肝硬化严重感染患者微生物丰富度降低,支持肝硬化的附加病理生物学效应。

研究设计与样本

  • 研究纳入15例健康对照、26例稳定期肝硬化、46例失代偿期肝硬化、14例慢加急性肝衰竭和14例无肝硬化严重感染患者。
  • 对配对唾液和粪便样本进行宏基因组测序,基于属聚类评估唾液型和肠型,并分析口腔和肠道生态位的毒力因子与抗菌药物耐药基因。

主要发现

  • 随着肝硬化严重程度和高氨血症增加,唾液型和肠型中致病菌比例增加,常驻菌减少。
  • 失代偿期肝硬化和慢加急性肝衰竭患者口腔与肠道微生物组重叠较稳定期肝硬化和健康对照增加,独立于抗菌药、β受体阻滞剂和抑酸治疗。
  • 失代偿期肝硬化和慢加急性肝衰竭中,两个不同的肠道微生物组簇携带PTS(磷酸烯醇丙酮酸:糖磷酸转移酶系统)及其他毒力因子基因。
  • 检出大量抗菌药物耐药基因(口腔1218个、肠道672个),其中575个为口腔和肠道共有。
  • 肝硬化耐药组独特,分别鉴定出3种口腔耐药型和4种肠道耐药型。

关键数值与推荐

  • 口腔抗菌药物耐药基因1218个,肠道672个,其中575个为口腔和肠道共有。
  • 鉴定出3种口腔耐药型和4种肠道耐药型。

临床怎么用

  • 作者认为这些见解可指导开发针对微生物组的靶向治疗和个体化抗菌方案,以减少肝硬化患者感染并发症并改善临床结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Cirrhosis complications are often triggered by bacterial infections with multidrug-resistant organisms. Alterations in the gut and oral microbiome in decompensated cirrhosis (DC) influence clinical outcomes. We interrogated: (i) gut and oral microbiome community structures, (ii) virulence factors (VFs) and antimicrobial resistance genes (ARGs) and (iii) oral-gut microbial overlap in patients with differing cirrhosis severity. METHODS: Fifteen healthy controls (HCs), as well as 26 patients with stable cirrhosis (SC), 46 with DC, 14 with acute-on-chronic liver failure (ACLF) and 14 with severe infection without cirrhosis participated. Metagenomic sequencing was undertaken on paired saliva and faecal samples. 'Salivatypes' and 'enterotypes' based on genera clustering were assessed against cirrhosis severity and clinical parameters. VFs and ARGs were evaluated in oral and gut niches, and distinct resistotypes identified. RESULTS: Salivatypes and enterotypes revealed a greater proportion of pathobionts with concomitant reduction in autochthonous genera with increasing cirrhosis severity and hyperammonaemia. Increasing overlap between oral and gut microbiome communities was observed in DC and ACLF vs. SC and HCs, independent of antimicrobial, beta-blocker and gastric acid-suppressing therapies. Two distinct gut microbiome clusters harboured genes encoding for the PTS (phosphoenolpyruvate:sugar phosphotransferase system) and other VFs in DC and ACLF. Substantial ARGs (oral: 1,218 and gut: 672) were detected (575 common to both sites). The cirrhosis resistome was distinct, with three oral and four gut resistotypes identified, respectively. CONCLUSIONS: The degree of oral-gut microbial community overlap, frequency of VFs and ARGs all increase significantly with cirrhosis severity, with progressive dominance of pathobionts and loss of commensals. Despite similar antimicrobial exposure, patients with DC and ACLF have reduced microbial richness compared to patients with severe infection without cirrhosis, supporting the additive pathobiological effect of cirrhosis. IMPACT AND IMPLICATIONS: This research underscores the crucial role of microbiome alterations in the progression of cirrhosis in an era of escalating multidrug resistant infections, highlighting the association and potential impact of increased oral-gut microbial overlap, virulence factors, and antimicrobial resistance genes on clinical outcomes. These findings are particularly significant for patients with decompensated cirrhosis and acute-on-chronic liver failure, as they reveal the intricate relationship between microbiome alterations and cirrhosis complications. This is relevant in the context of multidrug-resistant organisms and reduced oral-gut microbial diversity that exacerbate cirrhosis severity, drive hepatic decompensation and complicate treatment. For practical applications, these insights could guide the development of targeted microbiome-based therapeutics and personalised antimicrobial regimens for patients with cirrhosis to mitigate infectious complications and improve clinical outcomes.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Lee S, Arefaine B, Begum N, et al. Oral-gut microbiome interactions in advanced cirrhosis: characterisation of pathogenic enterotypes and salivatypes, virulence factors and antimicrobial resistance. J Hepatol. 2024. PMID: 39447963. doi:10.1016/j.jhep.2024.09.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。